Ewing Weight Loss Clinic

Leading Injectable Weight Loss Medications

Ewing Weight Loss Clinic in Reno offers prescriptions for Tirzepatide and Semaglutide based weight loss drugs. Both offer variations of the GLP-1 receptor agonist (GLP-1 RA) that triggers a response in the nervous system, stomach, and digestive system, which together promote weight loss.

• Zepbound & Mounjaro (Tirzepatide) – Eli Lilly
  • Mechanism: Dual GIP and GLP-1 receptor agonist.
  • Efficacy: Average weight loss of ~25% over one year.
  • Notes: Approved for type 2 diabetes and obesity; considered most effective injectable option currently available.
• Wegovy & Ozempic (Semaglutide) – Novo Nordisk
  • Mechanism: GLP-1 receptor agonist.
  • Efficacy: Average weight loss of 15–17% over 68 weeks.
  • Notes: Widely prescribed; an oral version has been submitted for FDA approval.
• Saxenda (Liraglutide) – Novo Nordisk
  • Mechanism: GLP-1 receptor agonist.
  • Efficacy: Average weight loss of 5–7% over one year.
  • Notes: Administered daily; less potent than newer options.

Available at Ewing Weight Loss Clinic, GLP-1 receptor agonists, including Tirzepatide and Semaglutide, are effective for accelerated weight loss to achieve optimal personal health. Contact Us for details, or call: 775-322-3011.

Leading Oral Weight Loss Medications

• Rybelsus (Oral Semaglutide) – Novo Nordisk
  • Mechanism: GLP-1 receptor agonist.
  • Efficacy: Average weight loss of 15.1% over 68 weeks at a 50mg dose.
  • Notes: Currently approved for type 2 diabetes; higher-dose version submitted for FDA approval for weight loss.
• Orforglipron – Eli Lilly (Experimental)
  • Mechanism: Oral, non-peptide GLP-1 receptor agonist.
  • Efficacy: Demonstrated significant weight loss in Phase 3 trials for type 2 diabetes patients.
  • Notes: Still in clinical trials; offers a needle-free alternative.
• Contrave (Naltrexone/Bupropion)
  • Mechanism: Targets appetite and cravings.
  • Efficacy: Over 40% of users lose at least 5% of body weight within a year.
  • Notes: Especially useful for emotional eating.
• Qsymia (Phentermine/Topiramate ER)
  • Mechanism: Combines appetite suppression and satiety enhancement.
  • Efficacy: Approximately 70% of users lose at least 5% of body weight within a year.
  • Notes: Controlled substance; not recommended for individuals with certain health conditions.
• Orlistat (Xenical)
  • Mechanism: Blocks fat absorption.
  • Efficacy: 35% of users lose at least 5% of body weight over a year.
  • Notes: Available over-the-counter as Alli; may cause gastrointestinal side effects.

Emerging Treatments / In-Development

• Retatrutide – Eli Lilly
  • Mechanism: Triple agonist targeting GLP-1, GIP, and glucagon receptors.
  • Efficacy: Average weight loss of 24% in clinical trials.
  • Status: In Phase 3 trials; not yet FDA-approved.
• CagriSema (Cagrilintide/Semaglutide) – Novo Nordisk
  • Mechanism: Combination of amylin and GLP-1 receptor agonists.
  • Efficacy: Average weight loss of 20.4% over 68 weeks.
  • Status: In Phase 3 trials; not yet FDA-approved.